Hims & Hers Health ($HIMS) stock recently earned a new Buy rating from Barclays at a price target of $48. Barclays sees potential for over 20% ...

The telehealth sector continues to expand, but individual companies are navigating vastly different paths. Hims & Hers Health, after a powerful rally earlie ...

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

Virtual care is steadily expanding as a mainstream healthcare channel, with Hims & Hers Health, Inc. HIMS and Teladoc Health, ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

At last check, HIMS was up 0.8% to trade at $47.82. It looks like the stock could continue higher, too, as those recent losses placed the shares near a long-term trendline that has historically ...

Hims & Hers Health (HIMS) has been on a bumpy ride, with shares up sharply this year but giving back ground over the past 3 months. This has left investors debating what the next leg looks like. See ...

Virtual healthcare and physician-focused digital platforms are reshaping U.S. healthcare delivery, with Hims & Hers Health, Inc. HIMS and Doximity, Inc. DOCS at the forefront. Hims & Hers operates a ...